Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of joining the trial.
• People who are scheduled to receive a stem cell transplant from a donor (called an allogeneic transplant) for acute leukemia, with no leukemia cells circulating in the blood and fewer than 5% abnormal cells in the bone marrow.
• People who are scheduled to receive a donor stem cell transplant for a bone marrow disorder called myelodysplasia or chronic myelomonocytic leukemia, with no abnormal cells in the blood and fewer than 10% abnormal cells in the bone marrow.
• People whose transplant plan includes a high-intensity preparatory treatment (called myeloablative conditioning).
• People who have a suitable matched sibling or unrelated stem cell donor, where the donor's tissue type closely matches the patient's (specific matching levels apply — confirm with trial site), and the donor is willing and medically cleared to donate.
• People whose heart is pumping at least 45% of its normal capacity (based on a heart function test).
• People whose kidneys are filtering blood at a rate above a certain level (confirm exact threshold with trial site).
• People whose lungs are functioning at or above a minimum level on breathing tests (confirm exact thresholds with trial site).
• People whose liver test results are within acceptable ranges (confirm exact values with trial site).
• People who are able to carry out normal daily activities to a reasonable degree, based on a standard performance scale (confirm exact score requirement with trial site).
• Female patients who are not post-menopausal for at least one year or surgically sterilised must agree to use two effective forms of contraception, or completely abstain from heterosexual intercourse, from signing the consent form through 12 months after transplant.
• Male patients must agree to use effective barrier contraception or abstain from heterosexual intercourse from signing the consent form through 12 months after transplant, even if surgically sterilised.
• People whose plans for any ongoing medication after transplant are disclosed at enrolment, and who plan to use only permitted maintenance medications if any (certain targeted therapies are allowed — confirm which ones with trial site).
• People who are willing and able to give voluntary written consent to participate, understanding they may withdraw at any time without affecting their future care.

Who may not be able to join:

• People who have previously had a donor stem cell transplant.
• People whose cancer has spread to the central nervous system (brain or spinal cord).
• People whose acute myeloid leukemia developed from certain other blood disorders called myeloproliferative neoplasms or overlap syndromes (confirm specific diagnosis with trial site, as some cases may still be eligible).
• People who have an active bacterial, viral, or fungal infection that is not responding to treatment at the time of enrolment.
• People with active or inadequately treated tuberculosis (TB).
• People who are HIV-positive with a detectable level of virus in their blood (those with an undetectable viral load on treatment may still be considered eligible — confirm with trial site).
• People with uncontrolled hepatitis B or hepatitis C virus (certain controlled cases with treatment may still be considered eligible — confirm with trial site).
• People who have had a blood clot in a vein or artery (such as a deep vein clot, pulmonary embolism, stroke, or heart attack) within the past six months, or who have severe or uncontrolled heart conditions (confirm specific conditions with trial site). Note: blood clots caused by a medical catheter are not automatically disqualifying.
• People who are pregnant or breastfeeding.
• People with a serious medical or mental health condition that is likely to make participation in the trial difficult.
• People who have had another cancer in the past, with some exceptions: certain skin cancers and previously treated cervical changes in situ may be allowed, and cancers treated with curative intent five or more years ago may be permitted — cases treated more recently require review and approval by the trial team (confirm with trial site).
• People whose transplant plan includes certain immune-suppressing medications called ATG or alemtuzumab.
• People whose plan includes a procedure called prophylactic donor leukocyte infusion after transplant.
• People who have previously taken a medication called ruxolitinib.
• People who have used certain immune checkpoint inhibitor medications within the six months before starting the preparatory treatment (confirm specific drug types with trial site).
• People with a hereditary heart condition called congenital Long QT syndrome.

Important: Always verify eligibility with the trial site directly before applying.